We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ILU:ASXIluka Resources Limited Analysis

Data as of 2026-03-16 - not real-time

A$6.45

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Iluka Resources posted FY25 revenue of A$1.02 billion, a 19 % decline year‑on‑year, and recorded a A$288 million loss. Operating and profit margins remain deeply negative, reflecting ongoing cost pressures. The balance sheet is leveraged, with over A$1.1 billion of debt and a debt‑to‑equity ratio near 55 %. Despite the weak fundamentals, the share price of A$6.45 sits just above the 20‑day SMA of A$6.16 and comfortably above the 50‑day SMA, indicating short‑term technical support. The MACD line sits above its signal line, generating a bullish signal, while the RSI of 56 suggests the stock is not overbought. Current support at A$5.13 and a modest upside potential of roughly 4 % to the consensus target of A$6.7 further bolster the technical case. The market sentiment gauge is in “Greed” territory (72.9), implying investors are broadly optimistic.
However, cash flow is strained, with operating cash flow of –A$57 million and free cash flow of –A$410 million, making the 0.76 % dividend hard to sustain. The company’s rare‑earths expansion, highlighted by progress at Balranald and Eneabba, offers a potential growth catalyst as global demand for neodymium and other critical minerals accelerates. Analyst consensus (10 analysts) remains bullish with a “Buy” recommendation and a mean price target of A$6.72. Volatility is high (≈61 % over the past 30 days) and beta is below 1, indicating the stock moves sharply but with slightly lower market correlation. Geographic exposure across Australia, Asia, Europe and the Americas adds medium‑level geopolitical risk, while regulatory risk remains medium given mining licences and environmental approvals. The declining volume trend points to a modest liquidity concern, though average volumes still exceed one million shares daily. In summary, the stock trades at a modest premium to book (P/B ≈ 1.34) and appears fairly valued given its mixed growth‑value profile, but the dividend sustainability is questionable.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 6/10

Key Factors

  • Bullish MACD and SMA alignment
  • Price near technical support with limited downside
  • Positive market sentiment (Greed index)

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Progress in rare‑earths projects
  • High debt and negative cash flow limiting flexibility
  • Analyst consensus Buy with target price

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Long‑term demand for critical minerals
  • Sustained earnings pressure and dividend risk
  • Valuation near book value suggesting fair pricing

Key Metrics & Analysis

Financial Health

Revenue Growth-19.10%
Profit Margin-28.40%
P/E Ratio-93.7
ROE-13.02%
ROA-0.65%
Debt/Equity54.98
P/B Ratio1.3
Op. Cash FlowA$-57500000
Free Cash FlowA$-410249984

Technical Analysis

TrendBullish
RSI55.6
SupportA$5.13
ResistanceA$6.93
MA 20A$6.16
MA 50A$6.08
MA 200A$5.90
MACDBullish
VolumeDecreasing
Fear & Greed Index72.88

Valuation

Target PriceA$6.72
Upside/Downside4.33%
GradeFair
TypeBlend
Dividend Yield0.76%

Risk Assessment

Beta0.81
Volatility61.15%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.